Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand

© 2017 Treatment options for castration-resistant prostate cancer (CRPC) are available, but clear instructions for the selection of appropriate treatment are lacking. A meeting of urology experts based in Thailand was convened with the following objectives: (1) to reach a consensus and share real-li...

全面介紹

Saved in:
書目詳細資料
Main Authors: Bannakij Lojanapiwat, Choosak Pripatnanont, Vorapot Choonhaklai, Surithorn Soontornpun, Supon Sriplakich, Sunai Leewansangtong, Apirak Santi-ngamkun, Julin Opanuraks, Wisoot Kongcharoensombat, Bhapapak Na-Songkla, Wiroj Raksakul, Chagkrapan Predanon
格式: 雜誌
出版: 2018
主題:
在線閱讀:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85012939668&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/57751
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!
實物特徵
總結:© 2017 Treatment options for castration-resistant prostate cancer (CRPC) are available, but clear instructions for the selection of appropriate treatment are lacking. A meeting of urology experts based in Thailand was convened with the following objectives: (1) to reach a consensus and share real-life experiences about how to identify CRPC; (2) to choose the appropriate treatment for CRPC patients; (3) to evaluate disease progression using novel inhibitors of the androgen receptor pathway; (4) to identify the frequency of monitoring disease; and (5) to promote rational use of corticosteroids in CRPC patients. This consensus document can provide guidance to other urologists in Thailand to provide appropriate treatment to metastatic CRPC patients in a timely manner.